Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SHAYLA M BERGMANN

Allopathic & Osteopathic Physicians Pediatrics Pediatric Hematology-Oncology

NPI
1730143645
CMS profile
214770
Location
BEAUFORT, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$25,272.75

24 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Novo Nordisk Inc $25,089.60 22
GENZYME CORPORATION $112.95 1
Novartis Pharmaceuticals Corporation $70.20 1

Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SHAYLA M BERGMANN

NPI 1730143645 · CMS profile ID 214770

Allopathic & Osteopathic Physicians / Pediatrics / Pediatric Hematology-Oncology

BEAUFORT, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1730143645?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SHAYLA M BERGMANN, NPI 1730143645, CMS profile ID 214770. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1730143645?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). SHAYLA M BERGMANN, NPI 1730143645, CMS profile ID 214770. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1730143645?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
SHAYLA M BERGMANN, NPI 1730143645, CMS profile ID 214770, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1730143645?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

24 matching records · $25,272.75 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 24 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–24 of 24.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novo Nordisk Inc $912.3511/16/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002079897 CMS
Novo Nordisk Inc $4,031.2511/16/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002079929 CMS
Novo Nordisk Inc $1,500.0011/09/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002079917 CMS
Novo Nordisk Inc $61.0010/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002058195 CMS
Novo Nordisk Inc $70.0910/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002079789 CMS
Novo Nordisk Inc $172.8510/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002079811 CMS
Novo Nordisk Inc $196.8210/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002079819 CMS
Novo Nordisk Inc $763.8810/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002079873 CMS
Novo Nordisk Inc $4,218.7510/26/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002079955 CMS
Novartis Pharmaceuticals Corporation $70.2006/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991627091 CMS
Novo Nordisk Inc $1,500.0006/12/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002079905 CMS
Novo Nordisk Inc $70.0906/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002079779 CMS
Novo Nordisk Inc $151.4206/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002079801 CMS
Novo Nordisk Inc $259.3806/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002079831 CMS
Novo Nordisk Inc $384.2606/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002079843 CMS
Novo Nordisk Inc $861.4006/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002079883 CMS
Novo Nordisk Inc $4,218.7506/08/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002079943 CMS
GENZYME CORPORATION $112.9505/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050477295 CMS
Novo Nordisk Inc $478.5005/03/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002079859 CMS
Novo Nordisk Inc $103.2704/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003161631 CMS
Novo Nordisk Inc $104.8004/27/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003161639 CMS
Novo Nordisk Inc $554.1904/27/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003161647 CMS
Novo Nordisk Inc $632.8004/27/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003161657 CMS
Novo Nordisk Inc $3,843.7504/27/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003161665 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $33,400.59 36
PY2020 $17,392.19 22
PY2021 $28,307.86 31
PY2022 $56,578.29 50
PY2023 $25,272.75 24
PY2024 $93,551.59 58
PY2025 $32,786.96 24

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $182,096.67 57
PY2024 Recipient $330.00 1
PY2024 Principal investigator $123,216.25 29
PY2023 Recipient $7,690.97 4
PY2023 Principal investigator $204,898.80 60
PY2022 Recipient $2,500.00 1
PY2022 Principal investigator $196,214.82 57
PY2021 Principal investigator $297,011.90 78
PY2020 Principal investigator $507,163.73 79
PY2019 Recipient $14,782.04 33
PY2019 Principal investigator $370,237.09 52

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

85 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca UK Limited $9.53 12/31/2019 Non-covered Recipient Entity
Medical Univ Of South Carolina
HESTIA3 Efficacy and Safety of Ticagrelor in Ped No dispute reported 06/30/2026 685000563
Principal investigator 1 AstraZeneca UK Limited $402.11 12/31/2019 Non-covered Recipient Entity
Medical University Of South Carolin
HESTIA3 Efficacy and Safety of Ticagrelor in Ped No dispute reported 06/30/2026 685000571
Principal investigator 1 AstraZeneca UK Limited $867.85 12/31/2019 Non-covered Recipient Entity
Medical University Of South Carolina Cystic Fibrosis Program
HESTIA3 Efficacy and Safety of Ticagrelor in Ped No dispute reported 06/30/2026 685000589
Principal investigator 1 PFIZER INC. $8,510.00 12/26/2019 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIVIPANSEL GMI1070 IN THE TREATMENT OF VASOOCCLUSIVE CRISIS IN HOSPITALIZED SUBJECTS WITH SICKLE CELL DISEASE No dispute reported 06/30/2026 671663131
Principal investigator 1 PFIZER INC. $495.00 12/23/2019 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIVIPANSEL GMI1070 IN THE TREATMENT OF VASOOCCLUSIVE CRISIS IN HOSPITALIZED SUBJECTS WITH SICKLE CELL DISEASE No dispute reported 06/30/2026 671663201
Principal investigator 1 Novo Nordisk AS $6.50 12/18/2019 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
NN7088-4410 No dispute reported 06/30/2026 706695471
Principal investigator 1 Novo Nordisk AS $6.50 12/18/2019 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
NN7088-4410 No dispute reported 06/30/2026 706695473
Principal investigator 1 Novo Nordisk AS $6.50 12/18/2019 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
NN7088-4410 No dispute reported 06/30/2026 706695475
Principal investigator 1 Novo Nordisk AS $6.50 12/18/2019 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
NN7088-4410 No dispute reported 06/30/2026 706695477
Principal investigator 1 Novo Nordisk AS $6.50 12/18/2019 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
NN7088-4410 No dispute reported 06/30/2026 706695479
Principal investigator 1 Novo Nordisk AS $6.50 12/18/2019 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
NN7088-4410 No dispute reported 06/30/2026 706695481
Principal investigator 1 Novo Nordisk AS $6.50 12/18/2019 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
NN7088-4410 No dispute reported 06/30/2026 706695483
Principal investigator 1 Novo Nordisk AS $6.50 12/18/2019 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
NN7088-4410 No dispute reported 06/30/2026 706695485
Principal investigator 1 Novo Nordisk AS $6.50 12/18/2019 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
NN7088-4410 No dispute reported 06/30/2026 706695487
Principal investigator 1 Novo Nordisk AS $6.50 12/18/2019 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
NN7088-4410 No dispute reported 06/30/2026 706695489
Principal investigator 1 Novo Nordisk AS $6.50 12/18/2019 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
NN7088-4410 No dispute reported 06/30/2026 706695491
Principal investigator 1 Novo Nordisk AS $6.50 12/18/2019 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
NN7088-4410 No dispute reported 06/30/2026 706695493
Principal investigator 1 Novo Nordisk AS $6.50 12/18/2019 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
NN7088-4410 No dispute reported 06/30/2026 706695495
Principal investigator 1 Novo Nordisk AS $6.50 12/18/2019 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
NN7088-4410 No dispute reported 06/30/2026 706695497
Principal investigator 1 Novo Nordisk AS $6.50 12/18/2019 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
NN7088-4410 No dispute reported 06/30/2026 706695499
Principal investigator 1 Novo Nordisk AS $6.50 12/18/2019 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
NN7088-4410 No dispute reported 06/30/2026 706695501
Principal investigator 1 Novo Nordisk AS $6.50 12/18/2019 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
NN7088-4410 No dispute reported 06/30/2026 706695503
Principal investigator 1 Novo Nordisk AS $3,694.86 12/03/2019 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
NN7088-4410 No dispute reported 06/30/2026 692466061
Principal investigator 1 Shire North American Group Inc $1,772.00 11/08/2019 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3, PROSPECTIVE, MULTICENTER, UNCONTROLLED, OPEN-LABEL CLINICAL STUDY TO DETERMINE THE EFFICACY, SAFETY, AND TOLERABILITY OF RVWF WITH OR WITHOUT ADVATE IN THE TREATMENT AND CONTROL OF BLEEDING EPISODES, THE EFFICACY AND SAFETY OF RVWF IN ELECTIVE AND EMERGENCY SURGERIES, AND THE PHARMACOKINETICS PK OF RVWF IN CHILDREN DIAGNOSED WITH SEVERE VON WILLEBRAND DISEASE No dispute reported 06/30/2026 637715163
Principal investigator 1 Shire North American Group Inc $1,582.00 11/08/2019 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3, PROSPECTIVE, MULTICENTER, UNCONTROLLED, OPEN-LABEL CLINICAL STUDY TO DETERMINE THE EFFICACY, SAFETY, AND TOLERABILITY OF RVWF WITH OR WITHOUT ADVATE IN THE TREATMENT AND CONTROL OF BLEEDING EPISODES, THE EFFICACY AND SAFETY OF RVWF IN ELECTIVE AND EMERGENCY SURGERIES, AND THE PHARMACOKINETICS PK OF RVWF IN CHILDREN DIAGNOSED WITH SEVERE VON WILLEBRAND DISEASE No dispute reported 06/30/2026 637715165
Principal investigator 1 Shire North American Group Inc $1,184.00 11/08/2019 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3, PROSPECTIVE, MULTICENTER, UNCONTROLLED, OPEN-LABEL CLINICAL STUDY TO DETERMINE THE EFFICACY, SAFETY, AND TOLERABILITY OF RVWF WITH OR WITHOUT ADVATE IN THE TREATMENT AND CONTROL OF BLEEDING EPISODES, THE EFFICACY AND SAFETY OF RVWF IN ELECTIVE AND EMERGENCY SURGERIES, AND THE PHARMACOKINETICS PK OF RVWF IN CHILDREN DIAGNOSED WITH SEVERE VON WILLEBRAND DISEASE No dispute reported 06/30/2026 637715167
Principal investigator 1 Shire North American Group Inc $123.10 11/08/2019 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3, PROSPECTIVE, MULTICENTER, UNCONTROLLED, OPEN-LABEL CLINICAL STUDY TO DETERMINE THE EFFICACY, SAFETY, AND TOLERABILITY OF RVWF WITH OR WITHOUT ADVATE IN THE TREATMENT AND CONTROL OF BLEEDING EPISODES, THE EFFICACY AND SAFETY OF RVWF IN ELECTIVE AND EMERGENCY SURGERIES, AND THE PHARMACOKINETICS PK OF RVWF IN CHILDREN DIAGNOSED WITH SEVERE VON WILLEBRAND DISEASE No dispute reported 06/30/2026 637715169
Principal investigator 1 Novo Nordisk AS $1,500.00 09/26/2019 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
NN7088-4410 No dispute reported 06/30/2026 692466053
Principal investigator 1 Novo Nordisk AS $1,000.00 09/26/2019 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
NN7088-4410 No dispute reported 06/30/2026 692466055
Principal investigator 1 Novo Nordisk AS $3,000.00 09/26/2019 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
NN7088-4410 No dispute reported 06/30/2026 692466057
Principal investigator 1 Novo Nordisk AS $1,560.00 09/26/2019 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
NN7088-4410 No dispute reported 06/30/2026 692466059
Principal investigator 1 PFIZER INC. $27,500.00 09/05/2019 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIVIPANSEL GMI1070 IN THE TREATMENT OF VASOOCCLUSIVE CRISIS IN HOSPITALIZED SUBJECTS WITH SICKLE CELL DISEASE No dispute reported 06/30/2026 671663133
Principal investigator 1 PFIZER INC. $104,000.00 09/05/2019 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIVIPANSEL GMI1070 IN THE TREATMENT OF VASOOCCLUSIVE CRISIS IN HOSPITALIZED SUBJECTS WITH SICKLE CELL DISEASE No dispute reported 06/30/2026 671663203
Principal investigator 1 PFIZER INC. $4,500.00 08/22/2019 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAGULATION FOR THE TREATMENT OF A VENOUS THROMBOEMBOLIC EVENT No dispute reported 06/30/2026 671662137
Principal investigator 1 Novo Nordisk AS $4,109.04 07/30/2019 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
NN7088-4410 No dispute reported 06/30/2026 692466051
Recipient Shire North American Group Inc $19.82 07/25/2019 Covered Recipient Physician A PHASE 12 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, ASCENDING DOSE, SAFETY AND PKPD STUDY OF SHP655 RADAMTS13 IN SICKLE CELL DISEASE AT BASELINE HEALTH AND DURING ACUTE VASO-OCCLUSIVE CRISIS No dispute reported 06/30/2026 637702573
Recipient Shire North American Group Inc $45.00 07/25/2019 Covered Recipient Physician A PHASE 12 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, ASCENDING DOSE, SAFETY AND PKPD STUDY OF SHP655 RADAMTS13 IN SICKLE CELL DISEASE AT BASELINE HEALTH AND DURING ACUTE VASO-OCCLUSIVE CRISIS No dispute reported 06/30/2026 637702575
Recipient Shire North American Group Inc $49.88 07/25/2019 Covered Recipient Physician A PHASE 12 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, ASCENDING DOSE, SAFETY AND PKPD STUDY OF SHP655 RADAMTS13 IN SICKLE CELL DISEASE AT BASELINE HEALTH AND DURING ACUTE VASO-OCCLUSIVE CRISIS No dispute reported 06/30/2026 637702577
Recipient Shire North American Group Inc $27.33 07/25/2019 Covered Recipient Physician A PHASE 12 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, ASCENDING DOSE, SAFETY AND PKPD STUDY OF SHP655 RADAMTS13 IN SICKLE CELL DISEASE AT BASELINE HEALTH AND DURING ACUTE VASO-OCCLUSIVE CRISIS No dispute reported 06/30/2026 637702579
Recipient Shire North American Group Inc $65.60 07/25/2019 Covered Recipient Physician A PHASE 12 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, ASCENDING DOSE, SAFETY AND PKPD STUDY OF SHP655 RADAMTS13 IN SICKLE CELL DISEASE AT BASELINE HEALTH AND DURING ACUTE VASO-OCCLUSIVE CRISIS No dispute reported 06/30/2026 637702581
Recipient Shire North American Group Inc $23.67 07/25/2019 Covered Recipient Physician A PHASE 12 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, ASCENDING DOSE, SAFETY AND PKPD STUDY OF SHP655 RADAMTS13 IN SICKLE CELL DISEASE AT BASELINE HEALTH AND DURING ACUTE VASO-OCCLUSIVE CRISIS No dispute reported 06/30/2026 637702583
Recipient Shire North American Group Inc $193.55 07/24/2019 Covered Recipient Physician A PHASE 12 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, ASCENDING DOSE, SAFETY AND PKPD STUDY OF SHP655 RADAMTS13 IN SICKLE CELL DISEASE AT BASELINE HEALTH AND DURING ACUTE VASO-OCCLUSIVE CRISIS No dispute reported 06/30/2026 637702561
Recipient Shire North American Group Inc $49.88 07/24/2019 Covered Recipient Physician A PHASE 12 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, ASCENDING DOSE, SAFETY AND PKPD STUDY OF SHP655 RADAMTS13 IN SICKLE CELL DISEASE AT BASELINE HEALTH AND DURING ACUTE VASO-OCCLUSIVE CRISIS No dispute reported 06/30/2026 637702563
Recipient Shire North American Group Inc $25.29 07/24/2019 Covered Recipient Physician A PHASE 12 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, ASCENDING DOSE, SAFETY AND PKPD STUDY OF SHP655 RADAMTS13 IN SICKLE CELL DISEASE AT BASELINE HEALTH AND DURING ACUTE VASO-OCCLUSIVE CRISIS No dispute reported 06/30/2026 637702565
Recipient Shire North American Group Inc $73.80 07/24/2019 Covered Recipient Physician A PHASE 12 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, ASCENDING DOSE, SAFETY AND PKPD STUDY OF SHP655 RADAMTS13 IN SICKLE CELL DISEASE AT BASELINE HEALTH AND DURING ACUTE VASO-OCCLUSIVE CRISIS No dispute reported 06/30/2026 637702567
Recipient Shire North American Group Inc $25.29 07/24/2019 Covered Recipient Physician A PHASE 12 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, ASCENDING DOSE, SAFETY AND PKPD STUDY OF SHP655 RADAMTS13 IN SICKLE CELL DISEASE AT BASELINE HEALTH AND DURING ACUTE VASO-OCCLUSIVE CRISIS No dispute reported 06/30/2026 637702569
Recipient Shire North American Group Inc $130.00 07/24/2019 Covered Recipient Physician A PHASE 12 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, ASCENDING DOSE, SAFETY AND PKPD STUDY OF SHP655 RADAMTS13 IN SICKLE CELL DISEASE AT BASELINE HEALTH AND DURING ACUTE VASO-OCCLUSIVE CRISIS No dispute reported 06/30/2026 637702571
Recipient Shire North American Group Inc $490.74 07/23/2019 Covered Recipient Physician A PHASE 12 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, ASCENDING DOSE, SAFETY AND PKPD STUDY OF SHP655 RADAMTS13 IN SICKLE CELL DISEASE AT BASELINE HEALTH AND DURING ACUTE VASO-OCCLUSIVE CRISIS No dispute reported 06/30/2026 637702551
Recipient Shire North American Group Inc $84.46 07/23/2019 Covered Recipient Physician A PHASE 12 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, ASCENDING DOSE, SAFETY AND PKPD STUDY OF SHP655 RADAMTS13 IN SICKLE CELL DISEASE AT BASELINE HEALTH AND DURING ACUTE VASO-OCCLUSIVE CRISIS No dispute reported 06/30/2026 637702553
Recipient Shire North American Group Inc $43.22 07/23/2019 Covered Recipient Physician A PHASE 12 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, ASCENDING DOSE, SAFETY AND PKPD STUDY OF SHP655 RADAMTS13 IN SICKLE CELL DISEASE AT BASELINE HEALTH AND DURING ACUTE VASO-OCCLUSIVE CRISIS No dispute reported 06/30/2026 637702555
Recipient Shire North American Group Inc $30.35 07/23/2019 Covered Recipient Physician A PHASE 12 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, ASCENDING DOSE, SAFETY AND PKPD STUDY OF SHP655 RADAMTS13 IN SICKLE CELL DISEASE AT BASELINE HEALTH AND DURING ACUTE VASO-OCCLUSIVE CRISIS No dispute reported 06/30/2026 637702557
Recipient Shire North American Group Inc $112.07 07/23/2019 Covered Recipient Physician A PHASE 12 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, ASCENDING DOSE, SAFETY AND PKPD STUDY OF SHP655 RADAMTS13 IN SICKLE CELL DISEASE AT BASELINE HEALTH AND DURING ACUTE VASO-OCCLUSIVE CRISIS No dispute reported 06/30/2026 637702559
Recipient Shire North American Group Inc $856.18 07/18/2019 Covered Recipient Physician A PHASE 12 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, ASCENDING DOSE, SAFETY AND PKPD STUDY OF SHP655 RADAMTS13 IN SICKLE CELL DISEASE AT BASELINE HEALTH AND DURING ACUTE VASO-OCCLUSIVE CRISIS No dispute reported 06/30/2026 637702549
Principal investigator 1 AstraZeneca UK Limited $109.80 07/11/2019 Non-covered Recipient Entity
Medical Univ Of South Carolina
HESTIA3 Efficacy and Safety of Ticagrelor in Ped No dispute reported 06/30/2026 685000559
Principal investigator 1 AstraZeneca UK Limited $4,633.00 07/11/2019 Non-covered Recipient Entity
Medical University Of South Carolin
HESTIA3 Efficacy and Safety of Ticagrelor in Ped No dispute reported 06/30/2026 685000567
Principal investigator 1 AstraZeneca UK Limited $9,999.15 07/11/2019 Non-covered Recipient Entity
Medical University Of South Carolina Cystic Fibrosis Program
HESTIA3 Efficacy and Safety of Ticagrelor in Ped No dispute reported 06/30/2026 685000579
Principal investigator 1 PFIZER INC. $376.68 07/11/2019 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAGULATION FOR THE TREATMENT OF A VENOUS THROMBOEMBOLIC EVENT No dispute reported 06/30/2026 671663205
Principal investigator 1 PFIZER INC. $500.00 06/27/2019 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIVIPANSEL GMI1070 IN THE TREATMENT OF VASOOCCLUSIVE CRISIS IN HOSPITALIZED SUBJECTS WITH SICKLE CELL DISEASE No dispute reported 06/30/2026 671657423
Principal investigator 1 PFIZER INC. $8,105.50 06/06/2019 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
AN OPENLABEL EXTENSION STUDY TO EVALUATE THE SAFETY OF RIVIPANSEL GMI1070 IN THE TREATMENT OF ONE OR MORE VASOOCCLUSIVE CRISES IN HOSPITALIZED SUBJECTS WITH SICKLE CELL DISEASE No dispute reported 06/30/2026 671653961
Principal investigator 1 PFIZER INC. $26,557.70 06/06/2019 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
AN OPENLABEL EXTENSION STUDY TO EVALUATE THE SAFETY OF RIVIPANSEL GMI1070 IN THE TREATMENT OF ONE OR MORE VASOOCCLUSIVE CRISES IN HOSPITALIZED SUBJECTS WITH SICKLE CELL DISEASE No dispute reported 06/30/2026 671654017
Principal investigator 1 PFIZER INC. $524.88 05/16/2019 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAGULATION FOR THE TREATMENT OF A VENOUS THROMBOEMBOLIC EVENT No dispute reported 06/30/2026 671655155
Principal investigator 1 PFIZER INC. $57,294.90 05/03/2019 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
AN OPENLABEL EXTENSION STUDY TO EVALUATE THE SAFETY OF RIVIPANSEL GMI1070 IN THE TREATMENT OF ONE OR MORE VASOOCCLUSIVE CRISES IN HOSPITALIZED SUBJECTS WITH SICKLE CELL DISEASE No dispute reported 06/30/2026 671654021
Principal investigator 1 PFIZER INC. $888.00 05/01/2019 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAGULATION FOR THE TREATMENT OF A VENOUS THROMBOEMBOLIC EVENT No dispute reported 06/30/2026 671653797
Principal investigator 1 PFIZER INC. $1,250.00 04/25/2019 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
AN OPENLABEL EXTENSION STUDY TO EVALUATE THE SAFETY OF RIVIPANSEL GMI1070 IN THE TREATMENT OF ONE OR MORE VASOOCCLUSIVE CRISES IN HOSPITALIZED SUBJECTS WITH SICKLE CELL DISEASE No dispute reported 06/30/2026 671654019
Principal investigator 1 Novartis Pharmaceuticals Corporation $83,997.49 04/17/2019 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 2 MULTICENTER OPEN LABEL STUDY TO ASSESS APPROPRIATE DOSING AND TO EVALUATE SAFETY OF CRIZANLIZUMAB WITH OR WITHOUT HYDROXYUREA HYDROXYCARBAMIDE IN SEQUENTIAL DESCENDING AGE GROUPS OF PEDIATRIC SICKLE CELL DISEASE PATIENTS WITH VASO OCCLUSIVE CRIS No dispute reported 06/30/2026 640720009
Recipient Shire North American Group Inc $13.47 04/05/2019 Covered Recipient Physician A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE VWD No dispute reported 06/30/2026 637702545
Recipient Shire North American Group Inc $151.25 04/05/2019 Covered Recipient Physician A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE VWD No dispute reported 06/30/2026 637702547
Principal investigator 1 PFIZER INC. $3,948.75 04/04/2019 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIVIPANSEL GMI1070 IN THE TREATMENT OF VASOOCCLUSIVE CRISIS IN HOSPITALIZED SUBJECTS WITH SICKLE CELL DISEASE No dispute reported 06/30/2026 671654089
Recipient Shire North American Group Inc $13.47 04/04/2019 Covered Recipient Physician A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE VWD No dispute reported 06/30/2026 637702537
Recipient Shire North American Group Inc $44.90 04/04/2019 Covered Recipient Physician A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE VWD No dispute reported 06/30/2026 637702539
Recipient Shire North American Group Inc $13.47 04/04/2019 Covered Recipient Physician A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE VWD No dispute reported 06/30/2026 637702541
Recipient Shire North American Group Inc $65.10 04/04/2019 Covered Recipient Physician A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE VWD No dispute reported 06/30/2026 637702543
Recipient Shire North American Group Inc $151.53 04/03/2019 Covered Recipient Physician A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE VWD No dispute reported 06/30/2026 637702521
Recipient Shire North American Group Inc $269.81 04/03/2019 Covered Recipient Physician A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE VWD No dispute reported 06/30/2026 637702523
Recipient Shire North American Group Inc $85.32 04/03/2019 Covered Recipient Physician A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE VWD No dispute reported 06/30/2026 637702525
Recipient Shire North American Group Inc $10.58 04/03/2019 Covered Recipient Physician A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE VWD No dispute reported 06/30/2026 637702527
Recipient Shire North American Group Inc $48.34 04/03/2019 Covered Recipient Physician A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE VWD No dispute reported 06/30/2026 637702529
Recipient Shire North American Group Inc $13.49 04/03/2019 Covered Recipient Physician A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE VWD No dispute reported 06/30/2026 637702531
Recipient Shire North American Group Inc $44.97 04/03/2019 Covered Recipient Physician A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE VWD No dispute reported 06/30/2026 637702533
Recipient Shire North American Group Inc $13.49 04/03/2019 Covered Recipient Physician A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE VWD No dispute reported 06/30/2026 637702535
Principal investigator 1 PFIZER INC. $1,495.00 03/28/2019 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
AN OPENLABEL EXTENSION STUDY TO EVALUATE THE SAFETY OF RIVIPANSEL GMI1070 IN THE TREATMENT OF ONE OR MORE VASOOCCLUSIVE CRISES IN HOSPITALIZED SUBJECTS WITH SICKLE CELL DISEASE No dispute reported 06/30/2026 671653959
Recipient Shire North American Group Inc $11,496.72 03/27/2019 Covered Recipient Physician A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE VWD No dispute reported 06/30/2026 637702519
Principal investigator 1 PFIZER INC. $969.48 03/26/2019 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAGULATION FOR THE TREATMENT OF A VENOUS THROMBOEMBOLIC EVENT No dispute reported 06/30/2026 671655177
Principal investigator 1 PFIZER INC. $2,778.77 02/12/2019 Non-covered Recipient Entity
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAGULATION FOR THE TREATMENT OF A VENOUS THROMBOEMBOLIC EVENT No dispute reported 06/30/2026 671663129
Principal investigator 1 PFIZER INC. $888.00 01/14/2019 Covered Recipient Teaching Hospital
MEDICAL UNIVERSITY OF SOUTH CAROLINA
A RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAGULATION FOR THE TREATMENT OF A VENOUS THROMBOEMBOLIC EVENT No dispute reported 06/30/2026 671654653